BACKGROUND	Using phase 3 trial data for sunitinib versus interferon ( IFN ) - in treatment-naive patients with metastatic renal cell carcinoma , retrospective analyses characterized sunitinib-associated fatigue and its impact on patient-reported health-related quality of life ( HRQoL ) .\